Ellagic acid represents a promising adjuvant in TNBC radiotherapy that may simultaneously enhance tumor sensitization and prevent radiation-induced cardiotoxicity.
Ellagic acid exhibits a unique dual function in TNBC radiotherapy: it sensitizes tumors by targeting the CARM1-CDK4 axis while protecting the heart through potent antioxidant activity. These findings position ellagic acid as a promising adjuvant candidate to enhance therapeutic efficacy and safety in TNBC radiotherapy.
Li et al. (Wed,) studied this question.